Weight Loss Injections Dubai Price Guide

How Much Do Weight Loss Injections Cost in Dubai?

If the search is specifically weight loss injections Dubai price, the first thing to understand is that Dubai does not have one clean market price for this category. The number changes with dose, brand, stock pressure, consultation fees, and channel. In practice, most Dubai buyers see four tiers:

• Lower-cost entry tier: Saxenda usually anchors the low end of approved monthly spend.
• Middle semaglutide tier: Ozempic can start lower at smaller pen strengths, but effective monthly spend climbs as refill pace increases.
• Higher-efficacy tier: Mounjaro usually prices above Ozempic but brings a stronger published tirzepatide signal.
• Highest approved semaglutide tier: Wegovy often sits highest on price and lowest on supply consistency.

A separate fifth lane is research-use retatrutide. That should not be mixed into the same pharmacy calculation because it is not an approved medicine in Dubai and is normally quoted per pen rather than as a clinic-led monthly refill.

Which Weight Loss Injection Is Usually Cheapest in Dubai?

On current Dubai pricing, Saxenda is usually the cheapest approved starting point. That lower price comes with a trade-off: daily injections and a weaker published weight-loss signal than semaglutide 2.4 mg or tirzepatide. For buyers prioritising lowest monthly spend first, Saxenda often wins. For buyers prioritising published efficacy per month spent, the conversation usually shifts to Ozempic or Mounjaro.

Ozempic can look cheaper at the start of a protocol, especially when the comparison is made at lower weekly doses. But once the question becomes, “What is my real monthly spend at the dose I am actually using?” the gap between Ozempic and other weekly options often narrows. That is why an article chasing buyer intent needs to separate starting price from true monthly refill cost.

Dubai Price Breakdown: Mounjaro, Ozempic, Wegovy, Saxenda, and Retatrutide

Mounjaro Price Dubai

Mounjaro price Dubai usually lands in the AED 1,500 to AED 2,500 per month range. The spend is higher than Ozempic in most side-by-side checks, but the trade-off is the stronger published tirzepatide signal. In SURMOUNT-1, tirzepatide reached up to 22.4% weight loss, which is why Mounjaro often dominates the “best approved signal” conversation even when it loses the “lowest price” conversation. For Dubai-specific access notes, see our Mounjaro in Dubai guide.

Ozempic Price Dubai

Ozempic price Dubai usually spans a wider range because buyers often compare different pen strengths, refill intervals, and dose targets. A practical range is AED 744 to AED 1,800 per month. Ozempic stays highly visible in Dubai search behaviour because it is familiar, widely discussed, and often easier to find than Wegovy. The key catch is that Ozempic is a semaglutide diabetes brand, so the buyer should separate that reality from the obesity-specific semaglutide conversation. For the local semaglutide angle, see our Ozempic in Dubai guide.

Wegovy Price Dubai

Wegovy price Dubai usually sits above Ozempic, commonly around AED 1,800 to AED 2,800 per month when stock is available. Wegovy is the cleaner obesity-labelled semaglutide story, but the biggest friction in Dubai is often not interest. It is consistent availability. Buyers searching this term are often less worried about whether Wegovy works and more worried about whether they can keep a reliable refill path. For the broader UAE context, see our Wegovy UAE guide.

Saxenda Price Dubai

Saxenda price Dubai usually starts around AED 800 to AED 1,200 per month, which is why it remains important in the lower-budget end of the market. The trade-off is daily injection burden plus lower published weight-loss signal than weekly tirzepatide or semaglutide. Saxenda often wins the affordability conversation, but it rarely wins the “strongest data” conversation.

Retatrutide Dubai Price

Retatrutide Dubai price belongs to a different category entirely. Retatrutide remains investigational, so it is not a Dubai pharmacy medicine. In the local research-supply context, it is normally quoted per pen, not as a monthly prescription refill. On current Remy references, the 20 mg pen starts around AED 1,200 and the 30 mg pen starts around AED 1,800, with deeper value at research volume. That price needs to be read together with the format: 300 clicks at 0.1 mg per click, Janoshik-backed batch flow, and no reconstitution. For the full proof trail, see Retatrutide Dubai and the COA library.

What Changes Weight Loss Injection Prices in Dubai?

The best-performing buyer pages do not stop at a list of prices. They explain why the prices move. In Dubai, five factors do most of the work:

• Dose intensity: the monthly spend rises as weekly dose rises, especially with semaglutide and tirzepatide protocols.
• Brand versus molecule: semaglutide and tirzepatide pricing depends on whether the search is for the molecule or a brand-specific access path.
• Supply pressure: Wegovy and Mounjaro pricing tends to become less predictable when local stock tightens.
• Clinic and consultation stack: some Dubai routes bundle consult fees or monitoring into the monthly number.
• Channel type: approved pharmacy products and research-use compounds should not be priced as if they belong to the same route.

That last point matters most for Retatrutide. A research-use pen with COA, fixed click math, and cold-chain handling is not the same purchase flow as an approved pharmacy injection. Lumping the two together makes the page less useful and less trustworthy.

Which Injection Has the Strongest Published Weight-Loss Data?

For buyers who care about value per published signal, the hierarchy stays consistent. Tirzepatide leads the approved field, semaglutide 2.4 mg sits behind it, and liraglutide sits further back. In published trial data:

• Tirzepatide: up to 22.4% in SURMOUNT-1
• Semaglutide 2.4 mg: about 14.9% in STEP 1
• Liraglutide 3.0 mg: about 8% in SCALE
• Retatrutide: 24.2% in Phase 2, but still investigational

That means the core Dubai decision is usually not, “Which one works at all?” It is, “Do I want the lowest spend, the strongest approved data, the easiest refill path, or the strongest research-only signal?” If the question is specifically about approved products, Mounjaro carries the strongest argument. If the question is specifically about research, Retatrutide leads the current published signal and connects naturally to our Retatrutide vs Tirzepatide vs CagriSema analysis.

Dubai Buyer Checklist Before Paying

Pages built for buyer intent work better when they end with a practical checklist. Before paying, check:

• Is this a pharmacy product or a research product? The answer changes the whole compliance and delivery framework.
• Is the quoted number monthly or per pen? That difference is where many weak comparison pages fail.
• Does the route depend on a prescription? Approved Dubai pharmacy products do.
• Is stock stable or intermittent? Wegovy and some Mounjaro routes can be more supply-sensitive.
• What proof accompanies the product? In the research category, COA and batch verification matter more than marketing copy.
• Does the page actually show the next step? For Mounjaro, Ozempic, Wegovy, and UAE GLP-1 context, follow the product-specific pages. For research-use retatrutide, follow the proof stack: Dubai page, pen guide, clicks guide, and calculator.